GEO series
RNA-Seq profiling of pre- and on-treatment tumor samples from breast cancer patients enrolled in the NeoTRIP trial.
GSE319641
Homo sapiens
Expression profiling by high throughput sequencing
401 samples
Submitted 2026/05/26
Platform GPL18573
Summary
Triple-negative breast cancer (TNBC) is immunogenic, but only a subset of patients benefits from neoadjuvant immune checkpoint inhibitors (ICIs) combined with chemotherapy. Predictive biomarkers to guide patient selection and treatment adaptation are lacking. In the NeoTRIPaPDL1 (NeoTRIP) Phase III trial, 280 high-risk TNBC patients were randomized to neoadjuvant carboplatin plus nab-paclitaxel (CT, n=142) or the same regimen with atezolizumab (CT/A, n=138). Tumor biopsies were collected at baseline and on the first day of the second cycle (D1C2). Longitudinal transcriptome sequencing and analyses of selected gene signatures were performed, including hallmark, ferroptosis-related, and immune cell type–specific signatures. Treatment-induced gene expression changes and association with pathological complete response were investigated.
Published in
Dugo M, Huang CS, Egle D et al.
· Annals of oncology : official journal of the European Society for Medical Oncology 2026
· PMID 42162664
· doi:10.1016/j.annonc.2026.05.694
This dataset
Download
Direct links to NCBI, no account and no request form: the whole study as GSE319641_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 401 samples. Raw sequencing reads are also available from ENA.
Also filed as BioProject PRJNA1424908. Searching any of these in the dataset finder brings you back here.
Study design
40 conditions, each sampled once — no replicated groups
Read from the first 40 of 401 sample titles: 40 distinct titles with little repetition. Check it against the sample list below before relying on it.
Samples in this study
0 selected
- GSM9521946 Tumor sample of patient TNBC00001 at baseline
- GSM9521947 Tumor sample of patient TNBC00001 at day 1 of cycle 2
- GSM9521948 Tumor sample of patient TNBC00988 at baseline
- GSM9521949 Tumor sample of patient TNBC01436 at baseline
- GSM9521950 Tumor sample of patient TNBC01436 at day 1 of cycle 2
- GSM9521951 Tumor sample of patient TNBC01926 at baseline
- GSM9521952 Tumor sample of patient TNBC03683 at baseline
- GSM9521953 Tumor sample of patient TNBC03683 at day 1 of cycle 2
- GSM9521954 Tumor sample of patient TNBC03920 at baseline
- GSM9521955 Tumor sample of patient TNBC03920 at day 1 of cycle 2
- GSM9521956 Tumor sample of patient TNBC04100 at baseline
- GSM9521957 Tumor sample of patient TNBC04687 at baseline
- GSM9521958 Tumor sample of patient TNBC05791 at baseline
- GSM9521959 Tumor sample of patient TNBC05791 at day 1 of cycle 2
- GSM9521960 Tumor sample of patient TNBC06123 at baseline
- GSM9521961 Tumor sample of patient TNBC06135 at baseline
- GSM9521962 Tumor sample of patient TNBC06135 at day 1 of cycle 2
- GSM9521963 Tumor sample of patient TNBC06324 at baseline
- GSM9521964 Tumor sample of patient TNBC06324 at day 1 of cycle 2
- GSM9521965 Tumor sample of patient TNBC06653 at baseline
- GSM9521966 Tumor sample of patient TNBC06653 at day 1 of cycle 2
- GSM9521967 Tumor sample of patient TNBC06775 at baseline
- GSM9521968 Tumor sample of patient TNBC07076 at day 1 of cycle 2
- GSM9521969 Tumor sample of patient TNBC07174 at baseline
- GSM9521970 Tumor sample of patient TNBC07348 at baseline
- GSM9521971 Tumor sample of patient TNBC07550 at baseline
- GSM9521972 Tumor sample of patient TNBC07550 at day 1 of cycle 2
- GSM9521973 Tumor sample of patient TNBC07711 at baseline
- GSM9521974 Tumor sample of patient TNBC07895 at baseline
- GSM9521975 Tumor sample of patient TNBC07895 at day 1 of cycle 2
- GSM9521976 Tumor sample of patient TNBC08166 at baseline
- GSM9521977 Tumor sample of patient TNBC08166 at day 1 of cycle 2
- GSM9521978 Tumor sample of patient TNBC08172 at baseline
- GSM9521979 Tumor sample of patient TNBC08670 at baseline
- GSM9521980 Tumor sample of patient TNBC09613 at baseline
- GSM9521981 Tumor sample of patient TNBC10344 at baseline
- GSM9521982 Tumor sample of patient TNBC10344 at day 1 of cycle 2
- GSM9521983 Tumor sample of patient TNBC10463 at baseline
- GSM9521984 Tumor sample of patient TNBC10463 at day 1 of cycle 2
- GSM9521985 Tumor sample of patient TNBC10855 at baseline
+ 361 more — browse all 401 samples with per-sample file links →
Similar datasets
- GSE328275 Single-cell RNA sequencing of CD45+ immune cells across primary tumor, sentinel tumor-draining lymph node, and axillary lymph node in treatment-naive triple-negative breast cancer 28 samples
- GSE267718 Single cell RNA sequencing (scRNAseq) of urine-derived cells, peripheral blood mononuclear (PBMC), and tumor cells from bladder cancer patients. 33 samples
- GSE342455 Transcriptomic profiling of tumor-associated macrophages following pharmacological SYK inhibition in a human breast cancer co-culture model 6 samples
- GSE323973 Expression profiling by high throughput sequencing of breast cancer 158 samples
- GSE283703 Transcriptome analysis of adult patients with severe Obstructive Sleep Apnea before and after CPAP treatment. 71 samples
- GSE228598 Gene expression profile at single cell level of Peritoneal Cells in Patients with Gastric Cancer 28 samples
- GSE303346 Single-Cell RNA-Seq Reveals Immunosuppressive Effects of Triple-Negative Breast Cancer–Derived Exosomes on NK Cell Responses 16 samples
- GSE303509 Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer 14 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.